Hereditary hemochromatosis genotypes and risk of ischemic stroke

Neurology

Volumn 68, Issue 13, 2007, Pages 1025-1031

  Ellervik, C ^a   Tybjaerg Hansen A ^b,c   Appleyard, M ^c   Sillesen, H ^b   Boysen, G ^c   Nordestgaard, B G ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENOTYPE; HAZARD RATIO; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DENMARK; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 34147135182     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000257814.77115.d6     Document Type: Article

References (41)

1. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-2397.
2. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
3. Ellervik C, Tybjaerg-Hansen A, Grande P, Appleyard M, Nordestgaard BG. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation 2005;112:185-193.
4. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-337.
5. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-2919.
6. Robson KJ, Lehmann DJ, Wimhurst VL, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 2004;41:261-265.
7. Candore G, Licastro F, Chiappelli M, et al. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 2003;124:525-528.
8. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004;25:465-474.
9. Pulliam JF, Jennings CD, Kryscio RJ, et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B 2003;119B:48-53.
10. Sampietro M, Caputo L, Casatta A, et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001;22:563-568.
11. Moalem S, Percy ME, Andrews DF, et al. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000;93:58-66.
12. Lleo A, Blesa R, Angelopoulos C, et al. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:820-821.
13. Guerreiro RJ, Bras JM, Santana I, et al. Association of HFE common mutations with Parkinsons disease, Alzheimers disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 2006;6:24.
14. Dekker MC, Giesbergen PC, Njajou OT, et al. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett 2003;348:117-119.
15. Borie C, Gasparini F, Verpillat P, et al. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 2002;249:801-804.
16. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett 2002;327:91-94.
17. Goodall EF, Greenway MJ, van MI, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005;65:934-937.
18. Ristic S, Lovrecic L, Brajenovic-Milic B, et al. Mutations in the hemochromatosis gene (HFE) and multiple sclerosis. Neurosci Lett 2005;383:301-304.
19. Wang XS, Lee S, Simmons Z, et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 2004;227:27-33.
20. Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH. HFE mutations are not strongly associated with sporadic ALS. Neurology 2004;62:1611-1612.
21. Rubio JP, Bahlo M, Tubridy N, et al. Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Hum Genet 2004;114:573-580.
22. Hetet G, Elbaz A, Gariepy J, et al. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest 2001;31:382-388.
23. Hruskovicova H, Milanez T, Kobal J, Potisk KP, Petrovic D, Peterlin B. Hemochromatosis-causing mutations C282Y and H63D are not risk factors for atherothrombotic cerebral infarction. Med Sci Monit 2005;11:BR248-BR252.
24. Njajou OT, Hollander M, Koudstaal PJ, et al. Mutations in the hemochromatosis gene (HFE) and stroke. Stroke 2002;33:2363-2366.
25. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-1273.
26. van Aken MO, de Craen AJM, Gussekloo J, et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus Study. Eur J Clin Invest 2002;32:750-754.
27. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum ferritin and C282Y mutation of the hemochromatosis gene as predictors of asymptomatic carotid atherosclerosis in a community population. Stroke 2000;31:3015-3020.
28. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-1477.
29. Connor JR. Iron transport proteins in the diseased brain. J Neurol Sci 2003;207:112-113.
30. Londrey GL, Spadone DP, Hodgson KJ, Ramsey DE, Barkmeier LD, Sumner DS. Does color-flow imaging improve the accuracy of duplex carotid evaluation? J Vasc Surg 1991;13:659-663.
31. Sillesen HH, Just SR, Hansen L, Schroeder TV. [Color Doppler ultrasound examination of carotid arteries.] Ugeskr Laeger 1994;156:7035-7038.
32. The Copenhagen City Heart Study Group. The Copenhagen City Heart Study. Østerbroundersøgelsen. A book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). Scand J Soc Med Suppl 1989;41:1-160.
33. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study. Østerbroundersøgelsen. Tables with data from the third examination 1991-1994. Eur Heart J 2001;3(Suppl H):1-83.
34. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001;358:1405-1409.
35. Truelsen T, Gronbaek M, Schnohr P, Boysen G. Stroke case fatality in Denmark from 1977 to 1992: the Copenhagen City Heart Study. Neuroepidemiology 2002;21:22-27.
36. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988;41:105-114.
37. Lindgren A, Norrving B, Rudling O, Johansson BB. Comparison of clinical and neuroradiological findings in first-ever stroke. A population-based study. Stroke 1994;25:1371-1377.
38. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
39. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-14028.
40. Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997;94:12384-12389.
41. Gochee PA, Powell LW, Cullen DJ, Du SD, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002;122:646-651.